Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v3-EN
Language English English
Date Updated 2021-04-02 2021-03-23
Drug Identification Number 02130955 02130955
Brand name TYPHIM VI TYPHIM VI
Common or Proper name Salmonella typhi Vi Capsular Polysaccharide Vaccine Salmonella typhi Vi Capsular Polysaccharide Vaccine
Company Name SANOFI PASTEUR LIMITED SANOFI PASTEUR LIMITED
Ingredients SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE
Strength(s) 25MCG 25MCG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 x 0.5 mL (single dose) syringe 1 x 0.5 mL (single dose) syringe
ATC code J07AP J07AP
ATC description BACTERIAL VACCINES BACTERIAL VACCINES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-04-01 2021-04-01
Actual start date 2021-04-01 2021-04-01
Estimated end date 2021-04-01 2021-04-01
Actual end date 2021-04-01 2021-04-01
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Sanofi Pasteur will be discontinuing the multidose vial presentation of Typhim Vi ® vaccine effective April 1st 2021. The single dose syringe presentation of Typhim Vi® will still be available to the market. ’Sanofi Pasteur will be discontinuing the multidose vial presentation of Typhim Vi ® vaccine effective April 1st 2021. The single dose syringe presentation of Typhim Vi® will still be available to the market.
Health Canada comments